← Back to news
April 15, 2026

FDA to Review Restrictions on Popular Peptide Injections

  • The FDA will meet in July to discuss easing restrictions on seven peptide injections, including BPC-157 and TB-500, which are popular among wellness influencers.
  • Health Secretary Robert F. Kennedy Jr. has publicly advocated for loosening regulations, citing personal benefits from peptide use.
  • The FDA plans to remove these peptides from a high-risk drug list, raising concerns about safety and the potential for an unregulated market.
  • Critics warn that allowing these peptides without thorough testing poses significant risks to public health.